Chemomab Therapeutics Ltd.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2017 | 1,610.2% | 1,610.2% | -469.9% |
| FY2018 | -140.7% | -140.7% | -108.1% |
| FY2019 | -219.2% | -219.2% | -137.3% |
| FY2020 | -55.1% | -55.1% | -47.7% |
| FY2021 | -20.3% | -20.3% | -19.4% |
| FY2022 | -76.3% | -76.3% | -64.2% |
| FY2023 | -142.5% | -142.5% | -109.3% |
| FY2024 | -103.0% | -103.0% | -82.2% |
| FY2025 | -72.9% | -72.9% | -65.1% |